N ucleic acid lipid particle vaccine

• Main Authors: KAWAOKA, YOSHIHIRO, ISHII, KEN, NAMBA, EIKO, JONAI, NAO, NIWA, TAKAKO, IMAI, KOIZUMI, MAKOTO, TOZUKA, MIYUKI, TAKESHITA, FUMIHIKO, KOBIYAMA, KOUJI, NAKAMURA, KENSUKE, OKA, TATSUYA, ONODERA, YOSHIKUNI, SUZUKI, TAKASHI, YAMAYOSHI, SEIYA
• Format: Patent
• Language: Chinese; English
• Published: 16.04.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

Provided is a vaccine for preventing and/or treating infection caused by the novel coronavirus (severe acute respiratory syndrome coronavirus 2: SARS-CoV-2). The lipid particles encapsulate a nucleic acid capable of expressing the S protein of the novel coronavirus (severe acute respiratory syndrome coronavirus 2: SARS-CoV-2) and/or a fragment thereof. The lipid contains a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof. In the formula, R1 and R2 independently indicate a C1-C3 alkyl group; L1 indicates a C17-C19 alkenyl group that may contain one or a plurality of C2-C4 alkanoyloxy groups; L2 indicates a C10-C19 alkyl group that may contain one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group that may contain one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.